Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population‐based series

Pool, Anne E. M. van der; Damhuis, Ronald A.; IJzermans, Jan N.M.; Wilt, Johannes H. W. de; Eggermont, A. M. M.; Kranse, Ries; Verhoef, C.

doi:10.1111/j.1463-1318.2010.02539.x

Cited by 205 publications

(125 citation statements)

References 37 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4] Studies have reported that >20% of CRC patients present with synchronous metastasis at primary staging. 5 Furthermore, cumulative rates of metachronous liver metastases of 4.3% have been reported at one-year follow-up, increasing up to 14.5% at five-year follow-up. 3 It has been hypothesised that these metachronous liver metastases may in fact develop from occult liver metastases that are already present at the time of primary staging.…”

Section: Introductionmentioning

confidence: 99%

Whole‐liver CT texture analysis in colorectal cancer: Does the presence of liver metastases affect the texture of the remaining liver?

et al. 2014

View full text Add to dashboard Cite

Background: Liver metastases limit survival in colorectal cancer. Earlier detection of (occult) metastatic disease may benefit treatment and survival. Objective: The objective of this article is to evaluate the potential of whole-liver CT texture analysis of apparently diseasefree liver parenchyma for discriminating between colorectal cancer (CRC) patients with and without hepatic metastases. Methods: The primary staging CT examinations of 29 CRC patients were retrospectively analysed. Patients were divided into three groups: patients without liver metastases (n ¼ 15), with synchronous liver metastases (n ¼ 10) and metachronous liver metastases within 18 months following primary staging (n ¼ 4). Whole-liver texture analysis was performed by delineation of the apparently non-diseased liver parenchyma (excluding metastases or other focal liver lesions) on portal phase images. Mean grey-level intensity (M), entropy (E) and uniformity (U) were derived with no filtration and different filter widths (0.5 ¼ fine, 1.5 ¼ medium, 2.5 ¼ coarse). Results: Mean E 1.5 and E 2.5 for the whole liver in patients with synchronous metastases were significantly higher compared with the non-metastatic patients (p ¼ 0.02 and p ¼ 0.01). Mean U 1.5 and U 2.5 were significantly lower in the synchronous metastases group compared with the non-metastatic group (p ¼ 0.04 and p ¼ 0.02). Texture parameters for the metachronous metastases group were not significantly different from the non-metastatic group or synchronous metastases group (p > 0.05), although -similar to the synchronous metastases group -there was a subtle trend towards increased E 1.5 , E 2.5 and decreased U 1.5 , U 2.5 values. Areas under the ROC curve for the diagnosis of synchronous metastatic disease based on the texture parameters E 1.5,2.5 and U 1.5,2.5 ranged between 0.73 and 0.78. Conclusion: Texture analysis of the apparently non-diseased liver holds promise to differentiate between CRC patients with and without metastatic liver disease. Further research is required to determine whether these findings may be used to benefit the prediction of metachronous liver disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Whole‐liver CT texture analysis in colorectal cancer: Does the presence of liver metastases affect the texture of the remaining liver?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…With more than 1.2 million new cases in 2008, colorectal cancer is the third most common form of cancer worldwide (1,2). Nearly 20% of patients are diagnosed at an advanced stage with metastatic disease (1) and over half will ultimately develop metachronous metastases.…”

Section: Introductionmentioning

confidence: 99%

“…Nearly 20% of patients are diagnosed at an advanced stage with metastatic disease (1) and over half will ultimately develop metachronous metastases. The recent development of targeted therapies has improved outcomes in patients with advanced colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Manceau

Imbeaud

Thiébaut

et al. 2014

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To identify microRNAs (miRNA) that predict response to anti-EGFR antibodies in patients with wild-type KRAS metastatic colorectal cancer (mCRC).Experimental Design: miRNA profiling was performed in a training set of 87 patients with mCRC refractory to chemotherapy treated with anti-EGFR antibodies. This included 33 fresh-frozen (FF) and 35 formalin-fixed paraffin-embedded (FFPE) samples retrospectively collected and 19 prospectively collected FF samples. An independent validation cohort consisting of 19 FF and 26 FFPE prospectively collected samples from patients with mCRC treated with anti-EGFR antibodies was used to confirm our findings.Results: After screening the expression of 1,145 miRNAs in FF samples from the training set, we identified that hsa-miR-31-3p expression level was significantly associated with progression-free survival (PFS). Statistical models based on miRNA expression discriminated between high and low risk of progression for both FF and FFPE samples. These models were confirmed in the validation cohort for both FF [HR, 4.1; 95% confidence interval (CI), 1.1-15.3; P < 0.04] and FFPE samples (HR, 2.44; 95% CI, 1.1-5.4; P ¼ 0.028). The percentage of variation of RECIST criteria in the validation series was significantly associated with the expression level of hsa-miR-31-3p (r 2 ¼ 0.49; P ¼ 0.0035) and risk status determined by hsa-miR-31-3p expression level (P ¼ 0.02, Kruskal-Wallis rank test). Nomograms were built and validated to predict PFSdepending on hsa-miR-31-3p expression level. Following in vitro studies, we identified 47 genes regulated by hsa-miR-31-3p. Conclusion: Hsa-miR-31-3p seems to be a new mCRC biomarker whose expression level allows for the identification of patients with wild-type KRAS mCRC who are more likely to respond to anti-EGFR therapy.

show abstract

“…The survival rate of CRC was detected at a localized stage is 90.3%. [6][7][8] It is known that approximately half of the CRC diagnosed patients will eventually progress with metastasis. Liver is known to be the most common metastatic site.…”

Section: Ivyspringmentioning

confidence: 99%

Colorectal Cancer from Molecular Pathways to Gene Therapy

Kosmıdis¹,

Efthimidis²,

Baka³

et al. 2017

Oncomedicine

View full text Add to dashboard Cite

Nowadays colorectal cancer is still considered the third most common cancer in the world. The tumorigenesis mechanisms of colorectal cancer have been widely studied at a molecular level. It has been observed that morbidity and mortality caused by colorectal cancer impacts on the global economy. This occurs through the loss of productivity and the burden on the healthcare system. Therefore an effort is made by several researchers to expend considerably their resources to develop treatments and preventative strategies to reduce the incidence of colorectal cancer. A Large-scale sequencing of genome, proteome, microbiome, and transcriptome analyses of colorectal cancer tissue has allowed researchers to better understand colorectal cancer subtypes. Until now the following parameters have been identified with the etiology of colorectal cancer genetic mutations, inflammatory processes, diet, and the gut microbes. In the current review we will present the molecular pathways of CRC and discuss novel gene therapy approaches.

show abstract

Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population‐based series

Abstract: Survival of patients with stage IV CRC has improved over time and this is probably a result of the increased use of chemotherapy and the increased numbers of patients who underwent hepatic surgery.

Cited by 205 publications

References 37 publications

Whole‐liver CT texture analysis in colorectal cancer: Does the presence of liver metastases affect the texture of the remaining liver?

Whole‐liver CT texture analysis in colorectal cancer: Does the presence of liver metastases affect the texture of the remaining liver?

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Colorectal Cancer from Molecular Pathways to Gene Therapy

Contact Info

Product

Resources

About